Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 07h15 HE
|
Clearside Biomedical, Inc.
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
09 nov. 2022 07h05 HE
|
Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
Ambulatory Surgical Centers Market to hit USD 144.5 billion by 2032, says Global Market Insights Inc.
09 nov. 2022 05h10 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Nov. 09, 2022 (GLOBE NEWSWIRE) -- The ambulatory surgical centers market value is estimated to exceed USD 144.5 billion by 2032, according to a new research report by Global...
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
08 nov. 2022 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley
08 nov. 2022 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other...
Global Dry Eye Treatment Devices Market Report 2022: High Incidence & Prevalence of Dry Eye Diseases Boosting Sector
08 nov. 2022 06h48 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast,...
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
02 nov. 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditions
31 oct. 2022 08h00 HE
|
KYS Vision, Inc.
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical trial results of its Macustat® macular function scan for the remote...
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
24 oct. 2022 13h05 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. OTCQB: RTGN to Present at the Emerging Growth Conference. RetinalGeniX Technologies, Inc. (RTGN) is pleased to...
$12+ Billion Diabetic Retinopathy Market Size to Grow at a CAGR of 6.5% by 2028 | The Insight Partners
19 oct. 2022 10h09 HE
|
The Insight Partners
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest market study on "Diabetic Retinopathy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19...